BRIEF-Incannex Completes Successful Pre-IND Meeting With FDA For CannQuit-N

Reuters02-16

Feb 16 (Reuters) - Incannex Healthcare Inc :

* INCANNEX COMPLETES SUCCESSFUL PRE-IND MEETING WITH THE FDA FOR CANNQUIT-N; A NOVEL SOLUTION FOR TOBACCO SMOKING CESSATION

* INCANNEX HEALTHCARE: FDA REVIEWED CANNQUIT-N MEETING PACKAGE AND PROVIDED RECOMMENDATIONS ON KEY DESIGN ASPECTS OF PROPOSED CLINICAL TRIALS

* INCANNEX HEALTHCARE INC: FDA ALSO CONFIRMED PROPOSED STRATEGIES FOR MANUFACTURING AND QUALITY CONTROL ARE APPROPRIATE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2411654418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-16 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2411654418","market":"us","top_or_hot":-1,"title":"BRIEF-Incannex Completes Successful Pre-IND Meeting With FDA For CannQuit-N","media":"Reuters","content":"<html><body><p>Feb 16 (Reuters) - Incannex Healthcare Inc   :</p><p>   * INCANNEX COMPLETES SUCCESSFUL PRE-IND MEETING WITH THE FDA FOR CANNQUIT-N; A NOVEL SOLUTION FOR TOBACCO SMOKING CESSATION</p><p>   * INCANNEX HEALTHCARE: FDA REVIEWED CANNQUIT-N MEETING PACKAGE AND PROVIDED RECOMMENDATIONS ON KEY DESIGN ASPECTS OF PROPOSED CLINICAL TRIALS</p><p>   * INCANNEX HEALTHCARE INC: FDA ALSO CONFIRMED PROPOSED STRATEGIES FOR MANUFACTURING AND QUALITY CONTROL ARE APPROPRIATE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Incannex Completes Successful Pre-IND Meeting With FDA For CannQuit-N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Incannex Completes Successful Pre-IND Meeting With FDA For CannQuit-N\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-16 20:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 16 (Reuters) - Incannex Healthcare Inc   :   * INCANNEX COMPLETES SUCCESSFUL PRE-IND MEETING WITH THE FDA FOR CANNQUIT-N; A NOVEL SOLUTION FOR TOBACCO SMOKING CESSATION   * INCANNEX HEALTHCARE: ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2411654418","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2411654418","pubTimestamp":1708087108,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 16  - Incannex Healthcare Inc   :   * INCANNEX COMPLETES SUCCESSFUL PRE-IND MEETING WITH THE FDA FOR CANNQUIT-N; A NOVEL SOLUTION FOR TOBACCO SMOKING CESSATION   * INCANNEX HEALTHCARE: FDA REVIEWED CANNQUIT-N MEETING PACKAGE AND PROVIDED RECOMMENDATIONS ON KEY DESIGN ASPECTS OF PROPOSED CLINICAL TRIALS   * INCANNEX HEALTHCARE INC: FDA ALSO CONFIRMED PROPOSED STRATEGIES FOR MANUFACTURING AND QUALITY CONTROL ARE APPROPRIATESource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IXHL":"INCANNEX HEALTHCARE LTD"},"translate_title":"简介-Incannex与FDA就CannQuit-N成功完成IND前会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXHL":0.9},"content_text":"Feb 16 (Reuters) - Incannex Healthcare Inc   :   * INCANNEX COMPLETES SUCCESSFUL PRE-IND MEETING WITH THE FDA FOR CANNQUIT-N; A NOVEL SOLUTION FOR TOBACCO SMOKING CESSATION   * INCANNEX HEALTHCARE: FDA REVIEWED CANNQUIT-N MEETING PACKAGE AND PROVIDED RECOMMENDATIONS ON KEY DESIGN ASPECTS OF PROPOSED CLINICAL TRIALS   * INCANNEX HEALTHCARE INC: FDA ALSO CONFIRMED PROPOSED STRATEGIES FOR MANUFACTURING AND QUALITY CONTROL ARE APPROPRIATESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2411654418"}